Skip to content
ESE logo
How ESE is Funded

The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2022 financial year.

ESE is funded through a number of industry and non-industry sources:

  • Membership – individual
  • Membership – Corporate – See all our Corporate members
  • Revenue generated by ESE owned journal ‘European Journal of Endocrinology
  • Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education 


  • Of the revenue into ESE in the 2022 accounts 41.5% was provided by industry.
  • The highest contribution from a single company represented 12.9% of the industry revenue and 5.3% of ESE revenue overall.
  1. Ascendis Pharma
  2. Berlin Chemie
  3. Bioscientifica
  4. Clinical Endocrinology Trust
  5. Consilient Health
  6. Corcept Therapeutics
  7. Crinetics Pharmaceuticals Inc.
  8. Cushing's Support and Research Foundation
  9. Diurnal Limited
  10. Eli Lilly
  11. Hemofarm
  12. HRA Pharma Rare Diseases
  13. Inozyme Pharma
  14. International Medical Press
  15. Ipsen
  16. Kyowa kirin
  17. Malvern Panalytical (for Concept Life Sciences)
  18. Medinfar
  19. Merck
  20. Neurocrine Biosciences
  21. Novo Nordisk Health Care AG
  22. Parathyroid UK
  23. Pfizer Ltd
  24. Radius Health
  25. Rare Bone Disease Consortium (COR2ED Agency)
  26. Recordati AG
  27. Rhythm Pharmaceuticals
  28. Savio Pharma
  29. Simple Pharma
  30. Soleno Therapeutics
  31. Springer Healthcare
  32. Spruce Biosciences
  33. Swixx Biopharma
  34. Takeda Pharmaceuticals International AG
  35. Thyroid Federation International
  36. Uni Pharma Kleon Tsetis
  37. Wisepress
  38. World Alliance of Pituitary Organizations (WAPO)